U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C26H29Cl2N5O3
Molecular Weight 530.446
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BOSUTINIB

SMILES

COC1=CC(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C(Cl)C=C1Cl

InChI

InChIKey=UBPYILGKFZZVDX-UHFFFAOYSA-N
InChI=1S/C26H29Cl2N5O3/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27/h11-14,16H,4-10H2,1-3H3,(H,30,31)

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including http://www.drugdevelopment-technology.com/projects/bosutinib-leukaemia/; http://www.pharmacodia.com/yaodu/html/v1/chemicals/d6bcb486f72ae7b5dc68b5b7df7ec887.html

Bosutinib (trade name Bosulif) originally synthesized by Wyeth, it is being developed by Pfizer. Bosutinib received US FDA and EU European Medicines Agency approval on September 4, 2012 and 27 March 2013 respectively for the treatment of adult patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance, or intolerance to prior therapy. Bosutinib is a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl and Src kinases with potential antineoplastic activity. Unlike imatinib, bosutinib inhibits the autophosphorylation of both Abl and Src kinases, resulting in inhibition of cell growth and apoptosis. Because of the dual mechanism of action, this agent may have activity in resistant CML disease, other myeloid malignancies and solid tumors. Abl kinase is upregulated in the presence of the abnormal Bcr-abl fusion protein which is commonly associated with chronic myeloid leukemia (CML). Overexpression of specific Src kinases is also associated with the imatinib-resistant CML phenotype.

CNS Activity

Curator's Comment: Bosutinib penetrates the brain, inhibits Abl activity and induces autophagic clearance of α-Synuclein and p-Tau in A53T mice and lentiviral gene transfer models. In another study it was shown that although bosutinib does show wide tissue distribution it but does not cross the blood brain barrier (http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd_smd_2014_bosulif_152211-eng.php)

Originator

Curator's Comment: The drug was originally developed by Wyeth Pharmaceuticals, which was taken over by Pfizer in October 2009.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P12931
Gene ID: 6714.0
Gene Symbol: SRC
Target Organism: Homo sapiens (Human)
1.2 nM [IC50]
Target ID: P00519
Gene ID: 25.0
Gene Symbol: ABL1
Target Organism: Homo sapiens (Human)
1.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
BOSULIF

Approved Use

Indicated for the treatment of adult patients with chronic, accelerated, or blast phase Ph+ chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy.

Launch Date

2012
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
273 ng/mL
500 mg 1 times / day multiple, oral
dose: 500 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
190 ng/mL
400 mg 1 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
76.6 ng/mL
300 mg 1 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
95.4 ng/mL
200 mg 1 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
19.6 ng/mL
100 mg 1 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
6.9 ng/mL
50 mg 1 times / day multiple, oral
dose: 50 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
4.89 ng/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
17 ng/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
43.1 ng/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
63.7 ng/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
117 ng/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
125 ng/mL
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
206 ng/mL
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
200 ng/mL
500 mg 1 times / day multiple, oral
dose: 500 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
200 ng/mL
500 mg 1 times / day steady-state, oral
dose: 500 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
216 ng/mL
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: HIGH-FAT
125 ng/mL
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
278.12 ng/mL
600 mg 1 times / day multiple, oral
dose: 600 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
62.1 ng/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
88 ng/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
3580 ng × h/mL
500 mg 1 times / day multiple, oral
dose: 500 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
2900 ng × h/mL
400 mg 1 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1170 ng × h/mL
300 mg 1 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1670 ng × h/mL
200 mg 1 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
329 ng × h/mL
100 mg 1 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
114 ng × h/mL
50 mg 1 times / day multiple, oral
dose: 50 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
129 ng × h/mL
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
284 ng × h/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
920 ng × h/mL
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1200 ng × h/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
2340 ng × h/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
2950 ng × h/mL
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
4300 ng × h/mL
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
3650 ng × h/mL
500 mg 1 times / day multiple, oral
dose: 500 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
3650 ng × h/mL
500 mg 1 times / day steady-state, oral
dose: 500 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
4000 ng × h/mL
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: HIGH-FAT
2950 ng × h/mL
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
4084.7 ng × h/mL
600 mg 1 times / day multiple, oral
dose: 600 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1150 ng × h/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
1768 ng × h/mL
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
23.3 h
500 mg 1 times / day multiple, oral
dose: 500 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
19.89 h
400 mg 1 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
19.4 h
300 mg 1 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
30 h
200 mg 1 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
64.7 h
100 mg 1 times / day multiple, oral
dose: 100 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
25.8 h
50 mg 1 times / day multiple, oral
dose: 50 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
12.9 h
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
18.6 h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
20.79 h
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
17.1 h
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
18.6 h
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
21.9 h
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
19.9 h
600 mg single, oral
dose: 600 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
22.5 h
500 mg 1 times / day steady-state, oral
dose: 500 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
33.8 h
800 mg single, oral
dose: 800 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: HIGH-FAT
21.9 h
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
15.4 h
600 mg 1 times / day multiple, oral
dose: 600 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
39.1 h
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
32.4 h
400 mg single, oral
dose: 400 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
4%
500 mg 1 times / day multiple, oral
dose: 500 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
4%
500 mg 1 times / day steady-state, oral
dose: 500 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
BOSUTINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
Doses

Doses

DosePopulationAdverse events​
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Sources:
unhealthy, 18-91 years
Health Status: unhealthy
Age Group: 18-91 years
Sex: M+F
Sources:
Disc. AE: Thrombocytopenia, Elevated liver enzymes...
AEs leading to
discontinuation/dose reduction:
Thrombocytopenia (29 patients)
Elevated liver enzymes (17 patients)
Neutropenia (11 patient)
Sources:
800 mg single, oral
Dose: 800 mg
Route: oral
Route: single
Dose: 800 mg
Sources:
healthy, adult
600 mg 1 times / day steady, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources:
unhealthy
AEs

AEs

AESignificanceDosePopulation
Neutropenia 11 patient
Disc. AE
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Sources:
unhealthy, 18-91 years
Health Status: unhealthy
Age Group: 18-91 years
Sex: M+F
Sources:
Elevated liver enzymes 17 patients
Disc. AE
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Sources:
unhealthy, 18-91 years
Health Status: unhealthy
Age Group: 18-91 years
Sex: M+F
Sources:
Thrombocytopenia 29 patients
Disc. AE
500 mg 1 times / day steady, oral
Recommended
Dose: 500 mg, 1 times / day
Route: oral
Route: steady
Dose: 500 mg, 1 times / day
Sources:
unhealthy, 18-91 years
Health Status: unhealthy
Age Group: 18-91 years
Sex: M+F
Sources:
OverviewDrug as perpetrator​Drug as victimTox targets

Tox targets

PubMed

PubMed

TitleDatePubMed
New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance.
2007 Jan
Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors.
2007 Sep
Targeted drugs in chronic myeloid leukemia.
2008
Gateways to clinical trials.
2008 Apr
Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).
2008 Feb
The chemistry of multi-protic drugs Part 1: a potentiometric, multi-wavelength UV and NMR pH titrimetric study of the micro-speciation of SKI-606.
2008 Jun 9
AXL is a potential target for therapeutic intervention in breast cancer progression.
2008 Mar 15
Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib.
2009 Feb 18
Severe toxicity of skin rash, fever and diarrhea associated with imatinib: case report and review of skin toxicities associated with tyrosine kinase inhibitors.
2009 Feb 6
New mechanisms of resistance in Philadelphia chromosome acute lymphoblastic leukemia.
2009 Jun
Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma.
2009 Jun
Bosutinib: a dual SRC/ABL kinase inhibitor for the treatment of chronic myeloid leukemia.
2009 Oct
Efficacy of dasatinib for the treatment of intractable chronic myeloid leukemia.
2010
Locking Src/Abl Tyrosine Kinase Activities Regulate Cell Differentiation and Invasion of Human Cervical Cancer Cells Expressing E6/E7 Oncoproteins of High-Risk HPV.
2010
[Development of ABL tyrosine kinase inhibitors].
2010 Aug
SRC: a century of science brought to the clinic.
2010 Aug
Optimizing combination therapies with existing and future CML drugs.
2010 Aug 23
Src inhibitors in lung cancer: current status and future directions.
2010 Jul 1
Gene expression analysis after receptor tyrosine kinase activation reveals new potential melanoma proteins.
2010 Jul 21
The dual kinase complex FAK-Src as a promising therapeutic target in cancer.
2010 Jun 24
Molecular measurement of BCR-ABL transcript variations in chronic myeloid leukemia patients in cytogenetic remission.
2010 Nov 18
Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.
2010 Nov 24
First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.
2010 Nov 26
Molecular characterization of c-Abl/c-Src kinase inhibitors targeted against murine tumour progenitor cells that express stem cell markers.
2010 Nov 30
Comprehensive analysis of kinase inhibitor selectivity.
2011 Oct 30
Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity.
2011 Oct 30
LRIG1 modulates cancer cell sensitivity to Smac mimetics by regulating TNFα expression and receptor tyrosine kinase signaling.
2012 Mar 1
Novel aspects of therapy with the dual Src and Abl kinase inhibitor bosutinib in chronic myeloid leukemia.
2012 Sep
Development and validation of a high-throughput intrinsic ATPase activity assay for the discovery of MEKK2 inhibitors.
2013 Apr
Patents

Sample Use Guides

Recommended Dose: 500 mg orally once daily with food. Consider dose escalation to 600 mg daily in patients who do not reach complete hematologic response by week 8 or complete cytogenetic response by week 12 and do not have Grade 3 or greater adverse reactions.
Route of Administration: Oral
Bosutinib potently inhibits Src-dependent cell proliferation with an IC50 of 100 nM.
Name Type Language
SK-606
Preferred Name English
BOSUTINIB
DASH   INN   MART.   MI   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
BOSUTINIB [USAN]
Common Name English
BOSULIF
Common Name English
BOSUTINIB [MI]
Common Name English
BOSUTINIB [MART.]
Common Name English
3-QUINOLINECARBONITRILE, 4-((2,4-DICHLORO-5-METHOXYPHENYL)AMINO)-6-METHYL-1-PIPERAZINYL)PROPOXY)-
Common Name English
4-[(2,4-Dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile
Systematic Name English
BOSUTINIB [VANDF]
Common Name English
SKI-606
Code English
bosutinib [INN]
Common Name English
Bosutinib [WHO-DD]
Common Name English
Classification Tree Code System Code
WHO-ATC L01XE14
Created by admin on Mon Mar 31 18:45:12 GMT 2025 , Edited by admin on Mon Mar 31 18:45:12 GMT 2025
FDA ORPHAN DRUG 274808
Created by admin on Mon Mar 31 18:45:12 GMT 2025 , Edited by admin on Mon Mar 31 18:45:12 GMT 2025
EU-Orphan Drug EU/3/10/762
Created by admin on Mon Mar 31 18:45:12 GMT 2025 , Edited by admin on Mon Mar 31 18:45:12 GMT 2025
NDF-RT N0000175605
Created by admin on Mon Mar 31 18:45:12 GMT 2025 , Edited by admin on Mon Mar 31 18:45:12 GMT 2025
LIVERTOX NBK547951
Created by admin on Mon Mar 31 18:45:12 GMT 2025 , Edited by admin on Mon Mar 31 18:45:12 GMT 2025
WHO-VATC QL01XE14
Created by admin on Mon Mar 31 18:45:12 GMT 2025 , Edited by admin on Mon Mar 31 18:45:12 GMT 2025
NCI_THESAURUS C155700
Created by admin on Mon Mar 31 18:45:12 GMT 2025 , Edited by admin on Mon Mar 31 18:45:12 GMT 2025
Code System Code Type Description
NDF-RT
N0000185503
Created by admin on Mon Mar 31 18:45:12 GMT 2025 , Edited by admin on Mon Mar 31 18:45:12 GMT 2025
PRIMARY P-Glycoprotein Inhibitors [MoA]
MESH
C471992
Created by admin on Mon Mar 31 18:45:12 GMT 2025 , Edited by admin on Mon Mar 31 18:45:12 GMT 2025
PRIMARY
CHEBI
39112
Created by admin on Mon Mar 31 18:45:12 GMT 2025 , Edited by admin on Mon Mar 31 18:45:12 GMT 2025
PRIMARY
IUPHAR
5710
Created by admin on Mon Mar 31 18:45:12 GMT 2025 , Edited by admin on Mon Mar 31 18:45:12 GMT 2025
PRIMARY
ChEMBL
CHEMBL288441
Created by admin on Mon Mar 31 18:45:12 GMT 2025 , Edited by admin on Mon Mar 31 18:45:12 GMT 2025
PRIMARY
MERCK INDEX
m2627
Created by admin on Mon Mar 31 18:45:12 GMT 2025 , Edited by admin on Mon Mar 31 18:45:12 GMT 2025
PRIMARY Merck Index
DRUG BANK
DB06616
Created by admin on Mon Mar 31 18:45:12 GMT 2025 , Edited by admin on Mon Mar 31 18:45:12 GMT 2025
PRIMARY
SMS_ID
100000090716
Created by admin on Mon Mar 31 18:45:12 GMT 2025 , Edited by admin on Mon Mar 31 18:45:12 GMT 2025
PRIMARY
USAN
RR-46
Created by admin on Mon Mar 31 18:45:12 GMT 2025 , Edited by admin on Mon Mar 31 18:45:12 GMT 2025
PRIMARY
LACTMED
Bosutinib
Created by admin on Mon Mar 31 18:45:12 GMT 2025 , Edited by admin on Mon Mar 31 18:45:12 GMT 2025
PRIMARY
EVMPD
SUB29176
Created by admin on Mon Mar 31 18:45:12 GMT 2025 , Edited by admin on Mon Mar 31 18:45:12 GMT 2025
PRIMARY
FDA UNII
5018V4AEZ0
Created by admin on Mon Mar 31 18:45:12 GMT 2025 , Edited by admin on Mon Mar 31 18:45:12 GMT 2025
PRIMARY
EPA CompTox
DTXSID10861568
Created by admin on Mon Mar 31 18:45:12 GMT 2025 , Edited by admin on Mon Mar 31 18:45:12 GMT 2025
PRIMARY
RXCUI
1307619
Created by admin on Mon Mar 31 18:45:12 GMT 2025 , Edited by admin on Mon Mar 31 18:45:12 GMT 2025
PRIMARY RxNorm
INN
8715
Created by admin on Mon Mar 31 18:45:12 GMT 2025 , Edited by admin on Mon Mar 31 18:45:12 GMT 2025
PRIMARY
PUBCHEM
5328940
Created by admin on Mon Mar 31 18:45:12 GMT 2025 , Edited by admin on Mon Mar 31 18:45:12 GMT 2025
PRIMARY
DAILYMED
5018V4AEZ0
Created by admin on Mon Mar 31 18:45:12 GMT 2025 , Edited by admin on Mon Mar 31 18:45:12 GMT 2025
PRIMARY
CHEBI
68533
Created by admin on Mon Mar 31 18:45:12 GMT 2025 , Edited by admin on Mon Mar 31 18:45:12 GMT 2025
PRIMARY
WIKIPEDIA
BOSUTINIB
Created by admin on Mon Mar 31 18:45:12 GMT 2025 , Edited by admin on Mon Mar 31 18:45:12 GMT 2025
PRIMARY
NCI_THESAURUS
C60809
Created by admin on Mon Mar 31 18:45:12 GMT 2025 , Edited by admin on Mon Mar 31 18:45:12 GMT 2025
PRIMARY
DRUG CENTRAL
4359
Created by admin on Mon Mar 31 18:45:12 GMT 2025 , Edited by admin on Mon Mar 31 18:45:12 GMT 2025
PRIMARY
CAS
380843-75-4
Created by admin on Mon Mar 31 18:45:12 GMT 2025 , Edited by admin on Mon Mar 31 18:45:12 GMT 2025
PRIMARY